Blue Water Biotech appoints Dr. Neil Campbell as CEO and Bruce Harmon as CFO effective October 4, 2023

Onconetix, Inc.

Dr. Neil Campbell appointed President & CEO and board member; replaces prior plan for James Sapirstein as Interim Executive Chairman.
Bruce Harmon appointed CFO, replacing Jon Garfield who resigned; Garfield receives $72,500 severance.
Campbell receives $75,000 signing bonus, $475,000 base salary, option to purchase 3% of outstanding shares.
Harmon receives $325,000 base salary, option to purchase 1% of outstanding shares.
James Sapirstein appointed non-executive Chairman of the Board.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jon Garfield

Chief Financial Officer

ONCO · Onconetix, Inc.

Effective: 2023-10-04
Filed: October 10, 2023, 7:59 PM ET

Effective as of October 4, 2023, Jon Garfield resigned as Chief Financial Officer of the Company.

Appointed

Neil Campbell

President and Chief Executive Officer

ONCO · Onconetix, Inc.

Effective: 2023-10-04
Filed: October 10, 2023, 7:59 PM ET

appointed Dr. Neil Campbell, 63, as President and Chief Executive Officer of the Company and as a member of the Board of Directors

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jon Garfield resigned as Chief Financial Officer at Onconetix, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

Effective as of October 4, 2023, Jon Garfield resigned as Chief Financial Officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Neil Campbell was appointed as President and Chief Executive Officer at Onconetix, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

appointed Dr. Neil Campbell, 63, as President and Chief Executive Officer of the Company and as a member of the Board of Directors

View on SEC.gov

Onconetix, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-081324

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.